Advanced search
Publication Cover
Leukemia & Lymphoma Volume 44, 2003 - Issue 4
Submit an article Journal homepage
38
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Cellular Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation: Experimental Strategies and Clinical Experiences

Hinrich Abken Klinik I für Innere Medizin, Labor Tumorgenetik, Universität zu Köln, Köln, Germany
,
Andreas Hombach Klinik I für Innere Medizin, Labor Tumorgenetik, Universität zu Köln, Köln, Germany
,
Günter Reinhard Klinik und Poliklinik für Dermatologie der Rheinischen Friedrich-Wilhelms-Universität, Bonn, Germany
,
Angela Märten Medizinische Universitätsklinik und Poliklinik I, Rheinische Friedrich-Wilhelms-Universität, Sigmund-Freud-Street 25, 53105 Bonn, Germany
,
Claudia Schlimper Radiologische Klinik und Poliklinik, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany
,
Axel Glasmacher Medizinische Universitätsklinik und Poliklinik I, Rheinische Friedrich-Wilhelms-Universität, Sigmund-Freud-Street 25, 53105 Bonn, Germany
,
Thomas Bieber Klinik und Poliklinik für Dermatologie der Rheinischen Friedrich-Wilhelms-Universität, Bonn, Germany
&
Ingo G.H. Schmidt-Wolf Medizinische Universitätsklinik und Poliklinik I, Rheinische Friedrich-Wilhelms-Universität, Sigmund-Freud-Street 25, 53105 Bonn, Germany
 show all
Pages 583-592 | Published online: 01 Jul 2009

  • Talmadge, J.K. Reed, K., lno, K., Kessinger, A., Kuszynski. C, Heimann, D., Varney, M., Jackson, J., Vose, J.M. and Bierman, P.J. (1997) "Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared tn hone marrow". Bone Marrow Transplant. 19, 161-172.
  • Avigan, D., Wu, Z., Joyce, R., Elias, A., Richardson, P., McDermott, D., Levine, J., Kennedy, L., Giallombardo, N., Hurley, D., Gong, J. and Kufe, D. (2000) "Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced hreast cancer". Bone Marrow Transplant. 26, 169-176.
  • Guillaume, T., Rubinstein, D.B. and Symann, M. (1999) "Immunological recovery and tumour-specific immunotherapeutic approaches to post-autologous haematopoietic stem cell transplantation". Baillieres Best Pract. Res. Clin. Haematol. 12, 293-306.
  • Grimm, K.A., Mazumder, A., Zhang, H.Z and Rosenberg, S.A. (1982) "Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes", J. Exp.Med. 155, 1823-1841.
  • Phillips, J.H and Lanjer, L.L. (1986) "Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis", J. Exp. Meet. 164, 814-825.
  • Benyunes, M.C., Higuchi, C., York, A. Lindgren, C., Thompson, J.A., Buckner, C.D. and Fefer, A. (1995) ''Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous hone marrow transplantation for malignant lymphoma: a feasibility trial". Bone Marnm Transplant. 16, 283-288.
  • Kaisanis.' K., Weisdorf, D.J. and Miller, J.S. (1998) "Activated peripheral blood mononuclear cells from patients receiving subcutaneous interleukin-2 following autologous stem cell transplantation prolong survival of SCID mice bearing human lymphoma". Bane Marrow Transplant 22, 185-191.
  • Gambacorti-Passerini, C., Rivoltini, L., Fizzotti. M. Rodolfo, M., Sensi, M.I., Castelli, C., Orazi, A., Polli, N., Bregni, M., Siena, S., et al. (1991 ) "Selective purging by human interleukin-2 activated lymphocytes of hone marrows contaminated with a lymphoma line or autologous leukaemic cells". Br. J. Haematol. 78, 197-205.
  • Klingemann, H.G., Deal, H., Reid, D. and Eaves, C.J. (1993)"Design and validation of a clinically applicable culture procedurefor the generation of interleukin-2 activated natural killer cells inhuman bone marrow autografts". Exp. Hematol. 21, 1263-1270.
  • Verma, U.N., Bagg, A., Brown, E. and Mazumder, A. (1994)"lnterleukin-2 activation of human bone marrow in long-termcultures: an effective strategy for purging and generation ofanti-tumor cylotoxic effectors". Bone Marrow Transplant. 13.115-123.
  • Hoffman, D.M., Gitlitz, B.J., Belldegnm, A. and Figlin, R.A. (2000)"Adoptive cellular therapy". Semin. Oncol. 27, 221-233.
  • deMagalhaes-Silverman, M., Donnenberg, A., Lembersky, B., Elder, E., Lister, J., Rybka, W., Whiteside, T. and Ball, E. (2000) "Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer", J. Immunother. 23, 154-160.
  • Clausen, J., Petzer, A.L., Vergeiner, B., Enk. M, Stauder, R., Gastl, G. and Gunsilius, E. (2001 ) "Optimal timing for the collection and in vitro expansion of cytotoxic CD56(+) lymphocytes from patients undergoing autologous peripheral blood stem cell transplantation", J Hematother. Stem Cell Res. 10, 513-521.
  • Schmidt-Wolf, I.G., Lefterova, P., Johnston, V. Huhn, D., Blume, K.G and Negrin, R.S. (1994) "Propagation of large numbers of T cells with natural killer cell markers". Br. J. Haematol. 87. 453-458.
  • Schmidt-Wolf, I.G. Lefterova, P., Mehta, B.A., Fernandez, L.P., Huhn, D., Blume, K.G., Weissman, I.L. and Negrin, R.S (1993) "Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells", Exp. Hematol. 21, 1671-1679.
  • Schmidt-Wolf, I.G. Negrin, R.S., Kiem, H.P., Blume, K.G. and Weissman, I.L. (1991) "Use of a SCID mouse/human lymphomn model to evaluate cytokine-induced killer cells with potent antitumor cell activity". J Exp. Med. 174, 139-149.
  • Schmidt, R.E., Murray, C., Daley, J.F., Schlossman, S.F. and Ritz, J. (1986) "A subset of natural killer cells in peripheral blood displays a mature T cell phenotype", J. Exp. Med. 164, 351-356.
  • Lanjer, L.L., Corliss. B and Phillips, J.H. (1997) "Arousal and inhibition of human NK cells", lmmunal. Rev 155, 145-154.
  • Lu, PH. and Negrin, R.S. (1994) "A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency", 1. Immunol. 153, 1687-1696.
  • Lopez, R.D., Waller, E.K., Lu, P.M. and Negrin, R.S. (2001) "CD58/LFA-3 and fL-12 provided by activated monocytes arc critical in the in vitro expansion of ("D56+ T cells". Caticet Inumnol. Immunother: 49, 629-640.
  • Zoll, B., Lefterova, P., Csipai, M., Finke, S., Trojaneck. B. Ehen, O., Micka, B., Roigk, K., Fehlinger, M., Schmidt-Wolf, G.D., Huhn, D. and Schmidt Wolf. LG. (1998) "Generation of 'cylokine-induced killer cells using exogenous interleukin-2. -7 or -12". Cancer Imunol, lmmunother: 47, 221-226.
  • Csipai, M., Lefterova, P., Hinke, S., Johnston, V., Scheffold, A., Huhn, D. and Schmidt-Wolf, 1. (1996) "Effects of interleukin-7 on proliferation of tumor cells". Cancer Kes. Ther. Contr. 5, 11-16.
  • Finke, S. Trojaneck, B., Leflerova, P., Csipai, M., Wagner, E., Kircheis, R., Neubauer, A., Huhn, D., Willig, B. and Schmidt-WoIf. LG. (1998) "Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3- CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene". Gene Ther. 5, 31-39.
  • Ortaldo, J.R., Winkler-Pickett, R.T. Yagila, H. and Young, H.A. (1991) "Comparative. studies of CD3- and CD34 CD56+ cells: examination of morphology, functions. T cell receptor rearrangement, and pore-forming protein expression". Cell. Immunol. 136. 486-495.
  • Scheffold, C., Brandt, K., Johnston, V., Lefterova, P., Degen, B., Schontube, M., Huhn, D., Neubauer, A. and Schmidt-Wolf. LG. (1995) "Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia". Bone Marrow Transplant. 15, 33-39
  • Mehta, B.A., Schmidt-Wolf. LG., Weissman, I.L. and Negnn, K.S. (1995) "Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3- CD56+ killer cells". Blood 86, 3493-3499.
  • Flieger, D., Kufer, P., Beier, I., Saucrbruch, T. and Schmidt-Wolf, I.G. (2000) "A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+ CD56+ natural-killer-like T lymphocytes to KpCAM-expressing tumor cells". Cancer lmmunol. lmmunother. 49, 441-448
  • Manen, A., Ziske. C. Sehonker, B., Renoth, S., Weineck, S., Buttgereit, P., Schakuwski, P., von Rucker, A., Sauerbruch. T and Schmidt-Wolf. LG. (2001) "Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations", J. lmmunother. 24, 502-510.
  • Schmidt-Wolf, I.G., Finke, S., Trojaneck, B., Denkena, A., Lefterova, P., Schwella, N., Heuft, H.G., Prange, O., Korte, M., Takeya, M., Dorbic, T., Neubauer, A., Wittig, B. and Huhn, D. (1999) "Phase 1 clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma". Br. J. Cancer 81, 1009-1016.
  • Marten, A., Schottker, B., Ziske, C., Weineck, S., Buttgereit, P., Huhn, D., Sauerbruch, T. and Schmidt-Wolf, l.G.H. (2000) "Increase of the immunostimulatory effect of dendritic cells by pulsing with CA 19-9 protein", J. Immunother. 23, 464-472
  • Rosenberg, S.A., Yannelli, J.R., Yang, J.C., Topalian, S.L. Schwartzentruber, D.J., Weber, J.S., Parkinson, D.R., Seipp. CA., Einhorn, J.H. and While, D.E. (1994) 'Treatment of patients with metastalic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2", J. NatI Cancer Inst. 86, 1159- 1166.
  • Zea, A.H. Curti, B.D. Longo, D.L., Alvord, W.G., Strobl, S.L., Mizoguchi, H., Creekmore, S.P., O'Shea, J.J., Powers, G.C., Urha, W.J., et al. (1995) "Alterations in T cell receptor and signal transduction molecules in melanoma patients ". Clin. Cancer Res, 1. 1327-1335.
  • Schwartz, R.H. (1990) "A cell culture model for T lymphocyte clonal anergy". Science 248, 1349-1356.
  • Matzinger, P. (1998) "An innate sense of danger". Semin, lmmunol. 10, 399-415.
  • Eggert, A.O., Becker, J.C., Ammon, M., MeLaellan, A.D., Renner, G., Merkel, A., Brocker, E.B and Kampgen, E (2002) "Specific peptide-mediated immunity against established melanoma tumors with dendritic cells requires 1L-2 and fetal call serum-free cell culture", Eur. J. lmmunol 32, 122-127.
  • Burt, R.K., Link, C. and Traynor, A. (1998) "Adoptive immunotherapy after hematopoietic stem cell transplantation". Curr. Opin. Oncol. 10, 525-532.
  • Kleihauer, A., Grigoleit, U., Hehart, H., Moris, A., Brossait, P., Muhm, A., Stevanovic. S. Rammensee, H.G., Sinzger. C'., Riegler, S., Jahn, G., Kanz, L. and Einsele, H. (2001 ) "Ex vivo generation of human cytomegulovims-specific cylotoxic T cells by peptidcpulsed dendritic cells". Br. J. Haematol. 113, 231-239.'
  • Lucas, K.G., Sun. 0. Burton, R.L., Tilden, A., Vaugban, W.P., Carabasi, M. Salzman, D. and Ship, A. (2000) "A phase I-II trial to examine the toxicity of CMV and EBV specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants". Hum Gene Ther 11, 1453-1463.
  • Szmania, S., Galloway, A., Bruorton, M., Musk, P., Aubert, G., Arthur, A., PyIe, H., Hensel, N., Ta, N., Lamb. Jr., L., Dodi, T. Madrigal, A. Barrett, J., Henslee-Downey, J. and van Rhee. K (2001) "Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers". Blood 98, 505-512.
  • Eshhar, Z. Waks, T., Bendavid, A. and Schindler, D.G. (2001) "Functional expression of chimeric receptor genes in human T cells". J lmmunol. Methods 248, 67-76.
  • Abken, H., Hombach, A., Reinhold. U and Ferrone, S. (1998) "Can combined T-cell-and antibody-based immunotherapy outsmart tumor cells?", lmmunol. Today 19, 2-5.
  • Hombach, A., Heuser, C. and Anken, H. (2002) "The recombinant T cell receptor strategy: insights into structure and function of recombinant immunorecepters on the way towards an optimal receptor design for cellular immunotherapy". Curr. Gene Ther 2. 211-226.
  • Hombach, A., Wieczarkowiecz., A., Manquardt, T., Heuser, C., Usai.I., Pohl, C., Seliger, B. and Ahken, H. (2001 )"Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient fL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule", J. Immunol. 167. 6123-6131.
  • [44| Hombach, A., Heuser. C'., Marquardt, T. Wieczarkowiecz, A., Groneek, V., Pohl, C. and Abken, H. (2001) "CD4-+ T cells engrafted with a recombinant immunoreceptor efficiently lyse target cells in a MHC antigen- and Fax-independent fashion", J. Immunol. 167, 1090-1096.
  • Hombach, A., Muche, J.M., Gerken, M., Gellrich, S., Heuser, C., Pohl, C., Sterry, W. and Abken, H. (2001 ) 'T cells engrafted with a recombinant umi-C'U30 receptor largei aulologous CD30(-rl cutaneous lymphnma cells". Gene Ther. 8, 891 -895.
  • Banchereau, J. and Steinmim, R.M. (1998) "Dendritic cells and the control of immunity". Nature 392, 245-252.
  • Naume, B., Gately, M. and Espevik, T. (1992) "A comparative study of IL-12 (cytotoxic lymphocyte maturation factor). 11-2-. andII.-7-induced effects on immunomagnetically purified CD56+ NK cells", J. lmmunol. 148, 2429-2436.
  • Margolin, K.A., Negrin, R.S., Wong, K.K., Challerjee, S., Wright, C. and Forman, S.J. (1997) "Cellular immunotherapy and autologous transplantation for hematologic malignancy", lmmunol. Rev 157, 231-240.
  • Caux, C., Massacrier, C., Vanhervliet, B., Duhois, B., Durand, L., Cella, M., Lanzavecehia, A. and Banchereau, J. (1997) "CD34+ hematopoietic progenitors from human cold blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumornecrosis factor alpha: II. Functional analysis". Blood 90. 1458-1470.
  • Caux, C., Vanbervliet, B., Massacrier, C., Dezutter-Dambuyant, C. de Saint-Vis, B., Jacquet, C., Yoneda, K., Imamura, S., Schmitt, D. and Banchereau, J. (1996) "CD34 + hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF + TNF alpha", J. Exp. Med. 184, 695-706.
  • Lanzavecchia, A. (1993) "Identifying strategies for immune intervention". Science 260, 937-944.
  • Sallusto, F. and Lanzavecchia, A. (1994) "Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating (actor plus interleukin 4 and downregulated by tumor necrosis factor alpha". 1. Exp. Med. 179, 1109-1118.
  • Siena, S., Di Nicola, M., Bregni, M., Mortarini, R. Anichini, A., Lombardi, I., Ravagnani, K. Parmiani, G. and Gianni, A.M. (1995) "Massive ex vivo generation of functional dendritic cells from mobilized CD34 - blood progenitors for anticancer therapy". Exp. Hematol. 23, 1463-1471.
  • Choi, D., Perrin, M., Hoffmann, S., Chang, A.H., Ratanathorathorn, V., Uberti. J. McDonagh, K.T. and Mule, J.J. (1998) "Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CO34 + cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells", Clin. Cancer Res, 4. 2709 2716.
  • [551 Mortarini, R., Anichini, A., Di Nicola, M., Siena, S., Bregni. Yl., Belli, F., MoIIa, A., Gianni, A.M and Parmiani, G. (1997) "Autologous dendritic cells derived from CD34 + progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-l(27-351-specific CTLs frorr peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors". Cancer Res 57, 5534-5541.
  • Romani, N., Gruner, S., Brang, D., Kampgen, E., Lenz, A., Trockenbacher, B., Konwalinka, G., Fritsch, P.O., Steinman, R.M. and Schuler, G. (1994) "Proliferating dendritic cell progenitors in human blood", J. Exp Med. 180, 83-93.
  • Thurner, B., Roder, C., Dieckmann, D., Heuer, M., Kruse, M., Glaser, A., Keikavoussi, P., Kampgen, E., Bender, A. and Schuler, G. (1999) "Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application", J. lmmunot. Methods 223, 1-15.
  • Jonuleit, H., Kuhn, U., Muller, G., Steinbrink, K., Paragnik, L., Schmitt, E., Knop, J. and Enk, A.H. (1997) "Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal call' serum-free conditions". Eur, J. lmmunol. 27, 3135-3142.
  • Bender, A., Sapp, M., Schuler, G., Steinman, R.M. and Bhardwaj, N. (1996) "Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood", J. lmmunol Methods 196, 121-135
  • Dhodapkar, M.V., Steinman, R.M., Sapp. M., Desai, H., Fossella, C., Krasovsky, J., Donahoe, S.M., Dunbar, P.R., Cerundolo, V., Nixon, D.F and Bhardwaj, N (1999) "Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells". J Clin. Investig. 104, 173-180.
  • Steinbrink, K., Jonuleit, H., Muller, G., Schuler, G., Knop, J. and Enk, A.M. (1999) "Tnterleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyae tumor cells". Blood 93. 1634-1642.
  • Junuleit, H., Schmitt, E., Schuler, G., Knop, J. and Enk, A.M. (2000) "Induction of interleukin 10-producing, nonproliferating CD4i+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells". J Exp. Med. 192. 1213-1222.
  • Thumer, B., Haendle, I. Roder, C., Dieckmann, D., Keikavoussi, P. Jonuleit, H., Bender, A., Maczek, C.,. Schreiner, D., von den Driesch, P. Brocker, E.B., Steinman, R.M., Enk, A., Kampgen, E and Schuler, G. (1999) "Vaccination with mage-3A l peplide-pulsed mature, monocyle-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma", J. Exp. Med. 190, 1669-1678.
  • Reinhard, G., Manen, A., Kiske, S.M., Feil, F., Bisher, T. and Schmidt-Wolf, I.G. (2002) "Generation of dendritic cell-based vaccines for cancer therapy", Br. J. Cancer 86, 1529-1533.
  • Bennett, S.R., Curbone, F.R., Karamalis, F., Flavell, R.A., Miller.J.F. and Heath, WR (1998) "Help for cytotoxic-T-cell responses ismediated by CD40 signalling". Nature 393, 478-480.
  • Ridge, J.P., Di Rosa. F, and Malzinger, P. (1998) "A conditioneddendritic cell can be a temporal bridge between a CD4 + T-helperand a T-killer cell". Nature 393, 474-478.
  • Schoenberger, S.P., Toes, R.E., van der Voort, E.I., Offringa, R andMelief, C.J. (1998) "T-cell help for cylotoxic T lymphocytes ismediated by CD40-CD40L interactions". Nature 393, 480-483.
  • Bocchia, M., Bronte, V., Colombo, M.P., De Vincentiis, A., DiNicola, M., Fomi, G., Lanata, L. Lemoli, R.M., Massaia, M.,Rondelli, D., Zanon, P. and Tura, S. (2000) "Antitumor vaccination:where we stand". Haematologica, 85, 1172-1206.
  • Kugler, A., Stuhler, G., Waiden, P., Toller, G., Zobywalski, A.,Brossait, P., Trefzer, L'., Ullrich, S. Muller, C.A., Becker, V, Gross,AJ., Hemmerlein, B., Kanz, L., Muller, G.A. and Ringen, R.H.(2000) "Regression of human metastatic renal cell carcinoma aftervaccination with tumor cell dendritic cell hybrids". Nat. Med, 6.332-336.
  • Timmerman, J.M., Czerwinski, O.K., Davis, T.A., Hsu. FJ., Benike.C., Hao, Z.M., Taidi, B., Rajapaksa, R., Caspar, C.B., Okada, CY.van Beekhoven, A., Lues, T.M., Engletnan, E.G. and Levy, R.(2002) "Idiotype-pulsed dendritic cell vaccination for B-celllymphoma: clinical and immune response* in 35 patients", Blood99, 1517-1526.
  • Schultze, J.L., and Nadler, L.M. (1999) "T cell mediatedimmunotherapy for B cell lymphoma", J. Mol. Med. 77, 322-331.
  • Wooldridge, J.E., Ballas, Z., Krieg, A.M. and Weiner, G.J. (1997)"Immunostimulatory oligodeoxynucleotides containing CpG motifsenhance the efficacy of monoclonal antibody therapy oflymphoma". Blood 89, 2994-2998.
  • Westermann, J., Aicher, A., Qin, Z., Cayeux, Z., Daemen. K,Blankenstein, T., Dorken, B. and Pezzutto, A. (1998) "Retroviralinterleukin-7 gene transfer into human dendritic cells enhancesT cell activation". Gene Ther, 5, 264-271
  • Zhang, W., Cao, X. and Huang, X. (1997) "In vivo induction ofantitumor immune response by tumor cells fused withGM-CSK gene-modified dendritic cells". Zhonbha YiXue ZaZhi77, 39-42.
  • Tuting, T., Wilson, C.C., Martin, D.M., Kasamon, V.L., Rowles, J.,Ma, D.I., Slingluff. Jr., C.L., Wagner, S.N., van der Bruggen, P.,Baar, J., Lotze, M.T. and Storkux, W.J. (1998) "Autologous humanmonocyte-derived dendritic cells genetically modified to expressmelanoma antigens elicit primary cytotoxic T cell responses invirm; enhancement by cotransfection of genes encoding the ThI-biasing cytokines IL-12 and IFN-alpha", J. lmmunol. 160,1139-1147.
  • Bordignon, C., Carlo-Stella, C., Colombo, M.P., De Vincentiis, A.,I-anata, L., Lemoli, R.M., Locatelli, K. Olivieri, A., Rondelli, D.,Zanon, P. and Tura, S. (1999) "Cell therapy: achievements andperspectives". Haematoloigica 84, 1110-1149.
  • Kwak, L.W. (1998) 'Tumor vaccination strategies combined withautologous peripheral stem cell transplantation". Ann. Oncol, 9.S41 -S46
  • Ruffini, P.A. and Kwak, L.W. (2001) "Immunotherapy of multiplemyeloma". Semin. Hematol. 38, 260-267
  • Bendandi, M. (2000) "Anti-idiotype vaccines for human follicularlymphoma". Leukemia 14, 1333-1339
  • Li, Y, Bendandi, M., Deng, Y. Dunbar, C, Munshi. N. Japannath.S., Kwak, L.W. and Lyerly, ILK. (2000) "Tumor-specificrecognition of human myeloma cells by idiotype-inducedCD8(+) T cells". Blood 96, 2828-2833.
  • Liso, A., Stockerl-Goldstein, K.F., Auffermann-Gretzinger, S.,Benike, C.J., Reichardt, V., van Beckhoven, A., Rajapaksa, R.,Engleman, F.,G., Blume, K.G. and Levy, R. (2000) "ldiotypevaccination using dendritic cells after autologous peripheral bloodprogenitor cell transplantation for multiple myeloma". Biol. BloodMarrow Transplant. 6, 621-627.
  • Massaia, M., Borrione, P., Batlaglio, S., Mariani, S., Beggiato, E.,Napoli, P. Voena, C., Bianchi, A. Coscia, M., Besostri, B., Peola,S., Stiefel, T., Even, J., Novero, D., Boccadoro, M. and Pileri, A.(1999) "ldiotype vaccination in human myeloma: generation oftumor-specific immune responses after high-dose chemotherapy".Blood 94, 673-683.
  • Reichardt, V.L., Okada, C.Y. Libo, A., Benike, C.J., Stockerl-Goldstein, K.K., Engleman, E.G., Blume, K.G. and Levy, R. (1999)"ldiotype vaccination using dendritic cells after autologousperipheral blood stem cell transplantation for multiple myeloma-a feasibility study". Blood 93, 2411-2419.
  • Steinman, R.M. (1991) "The dendritic cell system and its role inirnmunogenicily", Annu. Rev lmmunol. 9, 271-296.
  • Morse, M.A., Coleman, R.E., Mabani, G., Niehaus, N., Coleman.D. and Lyerly, H.K. (1999) "Migration of human dendritic cellsafter injection in patient.s with metastatic malignancies". CancerRes. 59, 56- 58.
  • Thomas, R., Chambers, M., Boytar, R., Barker, K., Cavanagh, L.L.,MacFadyen, S., Smithers, M., Jenkins. M and Andersen, J. (1999)"Immature human monocyte-derived dendritic cells migrate rapidlyto draining lymph nodes after intradermal injection for melanoma immunotheraphy". Melanoma Res. 9, 474-481.
  • Lambert, L.A., Gibson, G.R., Maloney, M., Durell, B., Noelle, R.J. and Barth. Jr., R.J. (2001) "Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity". Cancer Res. 61, 641-646.
  • Alvarnas, J.C., Linn, Y.C., Hope, E.G. and Negrin, R.S. (2001) "Expansion of cytotoxic CD3+ CD56- cells from peripheral blood progenitor cells of patients undergoing autologous hcinatnpoietic cell transplantation". Biol Blood Marrow Transplant, 7. 216-222

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.